<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00684099</url>
  </required_header>
  <id_info>
    <org_study_id>CT/05.18</org_study_id>
    <nct_id>NCT00684099</nct_id>
  </id_info>
  <brief_title>Docetaxel/Pemetrexed as 1st Line Treatment in Patients With Non Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Phase I/II Study Of The Docetaxel/Pemetrexed Combination As First Line Treatment In Patients With Advanced/Metastatic NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Oncology Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of Crete</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hellenic Oncology Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will determine the maximum tolerated dose the recommended phase II dose and the&#xD;
      efficacy of this combination in locally advanced or metastatic NSCLC patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Docetaxel as single-agent therapy (100 mg/m2 and 75 mg/m2, every 3 weeks) produces response&#xD;
      rates of 26% to 54%. Docetaxel has proven superior compared to best supportive care (BSC) in&#xD;
      chemotherapy-naïve as well as in platinum pretreated patients. In addition, docetaxel is&#xD;
      active in cisplatin refractory or resistant patients, producing responses ranging from 18% to&#xD;
      25%, implying a lack of cross-resistance between docetaxel and cisplatin, probably due to&#xD;
      their different mechanisms of action. Furthermore, docetaxel is associated with significant&#xD;
      prolongation of survival when administered as second line therapy, in pretreated patients&#xD;
      with advanced NSCLC. Phase II studies of pemetrexed in previously untreated patients with&#xD;
      NSCLC have demonstrated single agent response rates of 17% to 23%. A phase II study of&#xD;
      pemetrexed in patients with advanced NSCLC, who had progressed during or within 3 months of&#xD;
      completing first-line chemotherapy, demonstrated a response rate of 8.9% and median survival&#xD;
      time of 5.7 months. Multivariate analysis established an association between an increased&#xD;
      risk of severe pemetrexed toxicity and elevated homocysteine (folate and/or B12 vitamin&#xD;
      deficiency marker) levels. Since December 1999, all pemetrexed-treated patients are required&#xD;
      to receive folic acid and Vitamin B12. A recently reported phase III study compared&#xD;
      pemetrexed with docetaxel as 2nd line therapy in patients with advanced NSCLC. Treatment with&#xD;
      pemetrexed resulted in clinically equivalent efficacy outcomes, but with significantly fewer&#xD;
      side effects compared with docetaxel.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Dose Limited Toxicity and Maximum Tolerated Dose for the docetaxel/pemetrexed doublet</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate for the docetaxel/pemetrexed doublet</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel at starting dose of 65 mg/m2 IV on day 1 every 3 weeks for a total of 6 cycles</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed at starting dose of 400 mg/m2 IV on day 1 every 3 weeks for a total of 6 cycles</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed inoperable (stage IIIB-IV) NSCLC. A block of Formaline Fixed&#xD;
             Parafine Embedded tissue representative for the primary diagnosis should be available&#xD;
             for genomic analysis (phase II part)&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Prior chemotherapy with platinum compounds in association with or without taxanes&#xD;
             (phase I part)&#xD;
&#xD;
          -  Previously untreated with docetaxel and pemetrexed (phase II part)&#xD;
&#xD;
          -  Bidimensionally, non-irradiated measurable disease (according to RECIST criteria)&#xD;
             (phase II)&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  World Health Organization (WHO) performance status (PS) 0-2&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Serum bilirubin less than 1.5 times the upper normal limit (UNL)&#xD;
&#xD;
          -  AST and ALT less than 2.5 times the UNL in the absence of demonstrable liver&#xD;
             metastases, or less than 5 times the UNL in the presence of liver metastases.&#xD;
&#xD;
          -  Serum creatinine less than 1.5 times the UNL&#xD;
&#xD;
          -  Neutrophil count more than 1.5x 109 /L&#xD;
&#xD;
          -  Platelet count more than 100x 109 /L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other co-existing malignancies or malignancies diagnosed within the last 5 years (with&#xD;
             the exception of basal cell carcinoma or cervical cancer in situ)&#xD;
&#xD;
          -  Any evidence of severe uncontrolled concomitant disease (in the opinion of the&#xD;
             investigator)&#xD;
&#xD;
          -  Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer&#xD;
             therapy&#xD;
&#xD;
          -  Patients with unstable central nervous system metastases&#xD;
&#xD;
          -  Malnutrition (loss of ≥ 20% of the original body weight)&#xD;
&#xD;
          -  Performance status: 4&#xD;
&#xD;
          -  Psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vassilis Georgoulias, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Crete</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Athanasios Kotsakis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Crete</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University General Hospital of Alexandroupolis, Dep of Medical Oncology</name>
      <address>
        <city>Alexandroupolis</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;IASO&quot; General Hospital of Athnes, Dep of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Laikon&quot; General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Air Forces Military Hospital, Dep of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sismanogleio General Hospital, 1st, 2nd Dep of Pulmonary Diseases</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sotiria&quot; General Hospital, 1st Dep of Pulmonary Diseases</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Diabalkaniko&quot; Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Theagenion&quot; Anticancer Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>May 22, 2008</study_first_submitted>
  <study_first_submitted_qc>May 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2008</study_first_posted>
  <last_update_submitted>December 14, 2009</last_update_submitted>
  <last_update_submitted_qc>December 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>V.Georgoulias</name_title>
    <organization>University Hospital of Crete</organization>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>Pemetrexed</keyword>
  <keyword>Docetaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

